Finanzwire Finanzwire
Basculer en Français
11166 Companies
246602 Keywords
174550 Articles
133184 Press releases
Headlines Articles Press releases Clairvoyant Therapeutics Remove
  1. Home
  2. Companies
  3. Clairvoyant Therapeutics
Finanzwire
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 04/03/2024 at 14:05, 2 years 6 months ago

    Clairvoyant Therapeutics Advances Psilocybin Clinical Trial for Alcohol Use Disorder

    Clinical Trial Clairvoyant Therapeutics Psilocybin Treatment Alcohol Use Disorder Regulatory Pathway
  • PRESS RELEASE

    published on 04/03/2024 at 14:00, 2 years 6 months ago

    Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization

    Clairvoyant Therapeutics aims to commercialize psilocybin treatment for alcohol use disorder by 2025. Company's trial progressing well, expecting results in 2024 & financing round underway
    Commercialization Clinical Trial Clairvoyant Therapeutics Psilocybin Treatment Alcohol Use Disorder
    Logo of Clairvoyant Therapeutics
  • PRESS RELEASE

    published on 11/29/2023 at 13:00, 2 years 10 months ago

    Clairvoyant Surpasses 50 Per Cent Randomization in its Phase 2b Psilocybin Therapy Trial for Alcohol Use Disorder

    Logo of Clairvoyant Therapeutics
  • PRESS RELEASE

    published on 03/20/2023 at 12:00, 3 years 6 months ago

    First Patient Dosed in Europe in Clairvoyant’s Phase 2b Clinical Trial Exploring Psilocybin Therapy as a Treatment for Alcohol Use Disorder

    Logo of Clairvoyant Therapeutics
Accesswire
  • Published on 10/13/2026 at 15:00, 15 minutes ago

    Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend

  • Published on 10/13/2026 at 14:45, 30 minutes ago

    Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides

  • Published on 10/13/2026 at 14:31, 44 minutes ago

    First Breach Completes First Autonomous Flight of Proprietary Drone Prototype

  • Published on 10/13/2026 at 14:10, 1 hour 5 minutes ago

    NioCorp Places 100% of Its Planned Critical Minerals Production Under Commercial Sales Agreements

  • Published on 10/13/2026 at 14:00, 1 hour 15 minutes ago

    Orogen Royalties Enters into Agreement to Sell the Slaughterhouse Copper-Gold Project to Seabridge Gold

View all ACCESSWIRE
EQS Group
  • Published on 10/13/2026 at 15:06, 9 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.

  • Published on 10/13/2026 at 15:05, 10 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.

  • Published on 10/13/2026 at 15:05, 10 minutes ago

    Graylog v7.2 launches the Verascend™ Incident System, transforming how security teams detect and respond to threats

  • Published on 10/13/2026 at 15:03, 11 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: Permanent TSB Group Holdings plc

  • Published on 10/13/2026 at 15:02, 13 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: DCC plc

View all EQS
Les Echos
  • Published on 10/13/2026 at 09:04, 6 hours 10 minutes ago

    Peru Is Recognized as “South America's Leading Destination” at the World Travel Awards

  • Published on 10/12/2026 at 17:59, 21 hours 15 minutes ago

    Reporting on share buyback transactions carried out between October 7 and October 9, 2026

  • Published on 10/12/2026 at 17:45, 21 hours 30 minutes ago

    Weekly share buyback

  • Published on 10/12/2026 at 17:45, 21 hours 30 minutes ago

    Declaration of transactions on own shares from October 5, 2026 to October 11, 2026

  • Published on 10/12/2026 at 15:47, 23 hours 27 minutes ago

    Statement about the number of shares composing the share capital and the number of voting rights as of September 30, 2026

View all LES ECHOS COMFI WIRE

With finanzwire.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

Finanzwire

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

© 2026 Finanzwire

Contact Authors Cookies policy Terms and conditions Privacy policy